Synthesis of perhydro-1,4-ethano-1,5-naphthyridine and perhydro-4,7-ethanopyrrolo[3,2-b]pyridine derivatives: potential NK1-receptor antagonists. X-Ray molecular structures of (4aR,8S,8aR)-6-oxo-8-phenylperhydro-1,4-ethano-1,5-naphthyridine and (4aR,7R,8R,8aR)-7,8-diphenylperhydro-1,4-ethano-1,5-nap

Derivatives of perhydro-1,4-ethano-1,5-naphthyridine and 4,7-ethanopyrrolo[3,2-b]pyridine were designed and synthesized as conformationally constrained analogues of the potent NK1-receptor antagonist CP-96,345. 2-Benzylidenequinuclidin-3-one 1 was used as the common starting material: (i) heterocyclizations of compound 1 with N-(carbamoylmethyl)pyridinium chloride gave unsaturated pyridone derivatives which, after catalytic hydrogenation, afforded 1,5-naphthyridines, and (ii) functionalization of compound 1 by nucleophilic 1,4-addition reactions, followed by reductive cyclizations, gave quinuclidine derivatives with fused five- or six-membered rings. The cyclization reactions proceeded stereoselectively and the relative stereochemistries were determined by a combination of molecular mechanics calculations. X-Ray crystallography, and NMR spectroscopy. The biological activities of the synthesized derivatives were evaluated by binding studies to human NK1-receptors in UC11MG cells. The compounds had low to moderate affinity for the NK1-receptor.

[1]  J. Lowe,et al.  N-alkyl quinuclidinium substance P antagonists , 1994 .

[2]  J. Lowe,et al.  2-Aryl-1-azabicyclo[2.2.2]octanes as novel nonpeptide substance P antagonists , 1994 .

[3]  C. Fowler,et al.  Substance P enhances forskolin-stimulated cyclic AMP production in human UC11MG astrocytoma cells. , 1994, Methods and findings in experimental and clinical pharmacology.

[4]  M. Desai,et al.  Synthesis, in vitro binding profile, and autoradiographic analysis of [3H]-cis-3-[(2-methoxybenzyl)amino]-2-phenylpiperidine, a highly potent and selective nonpeptide substance P receptor antagonist radioligand. , 1993, Journal of medicinal chemistry.

[5]  C. Strader,et al.  Quinuclidine based NK-1 antagonists 2: determination of the absolute stereochemical requirements , 1993 .

[6]  C. Fowler,et al.  "Specific" binding of [3H]-[Sar9,Met(O2)11]-substance P to tissue culture plates is found when substance P is used to define non-specific binding. , 1993, Methods and findings in experimental and clinical pharmacology.

[7]  C. Strader,et al.  Quinuclidine-based NK-1 antagonists I: 3-benzyloxy-1-azabicyclo[2.2.2]octanes , 1993 .

[8]  J. Lowe,et al.  Nuclear variations of quinuclidine substance P antagonists: 2-diphenylmethyl-1-azabicyclo[3.2.2]nonan-3-amines , 1993 .

[9]  A. Barr,et al.  Non‐peptide antagonists, CP‐96,345 and RP 67580, distinguish species variants in tachykinin NK1 receptors , 1993, British journal of pharmacology.

[10]  P. Thadeio,et al.  Discovery of a potent substance P antagonist: recognition of the key molecular determinant. , 1992, Journal of medicinal chemistry.

[11]  Ralph Hirschmann,et al.  Nonpeptidal peptidomimetics with a β-D-glucose scaffolding. A partial somatostatin agonist bearing a close structural relationship to a potent, selective substance P antagonist , 1992 .

[12]  J. Lowe,et al.  The discovery of (2S,3S)-cis-2-(diphenylmethyl)-N-[(2-methoxyphenyl)methyl]-1- azabicyclo[2.2.2]-octan-3-amine as a novel, nonpeptide substance P antagonisst. , 1992, Journal of medicinal chemistry.

[13]  S. Guard,et al.  An SAR study for the non-peptide substance P receptor (NK1) antagonist, CP-96,345. , 1992 .

[14]  M. Logan,et al.  Synthesis and substance P antagonist activity of naphthimidazolium derivatives. , 1992, Journal of medicinal chemistry.

[15]  C. L. Johnson,et al.  Characterization of Receptors for Substance P in Human Astrocytoma Cells: Radioligand Binding and Inositol Phosphate Formation , 1992, Journal of neurochemistry.

[16]  M. Logan,et al.  Synthesis and substance P receptor binding activity of androstano[3,2-b]pyrimido[1,2-a]benzimidazoles. , 1992, Journal of medicinal chemistry.

[17]  J. Peyronel,et al.  Synthesis of RP-67,580, a new potent nonpeptide substance P antagonist , 1992 .

[18]  P. Laduron,et al.  Pharmacological properties of a potent and selective nonpeptide substance P antagonist. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[19]  M. Logan,et al.  Imidazo[4,5-b]quinoxaline cyanines as neurokinin antagonists. , 1991, Journal of medicinal chemistry.

[20]  J. Howbert,et al.  Selectivity and specificity of new, non-peptide, quinuclidine antagonists of substance P. , 1991, Biochemical and biophysical research communications.

[21]  A. Ganong,et al.  Activity and distribution of binding sites in brain of a nonpeptide substance P (NK1) receptor antagonist. , 1991, Science.

[22]  J. Lowe,et al.  A potent nonpeptide antagonist of the substance P (NK1) receptor. , 1991, Science.

[23]  J. Lowe,et al.  Preparation and radiolabelling of CP-96,345, the first non-peptide substance P antagonist , 1991 .

[24]  S. Nakanishi.  Mammalian tachykinin receptors. , 1991, Annual review of neuroscience.

[25]  G. Sheldrick.  Phase annealing in SHELX-90: direct methods for larger structures , 1990 .

[26]  M. Williams,et al.  4-(Phosphonoalkyl)- and 4-(phosphonoalkenyl)-2-piperidinecarboxylic acids: synthesis, activity at N-methyl-D-aspartic acid receptors, and anticonvulsant activity. , 1989, Journal of medicinal chemistry.

[27]  R. Snyderman,et al.  Substance P primes human neutrophil activation: a mechanism for neurological regulation of inflammation. , 1989, Biochemical and biophysical research communications.

[28]  D. Carson,et al.  Effect of neuropeptides on production of inflammatory cytokines by human monocytes , 1988 .

[29]  J. Glowinski,et al.  Substance P and neurokinin A regulate by different mechanisms dopamine release from dendrites and nerve terminals of the nigrostriatal dopaminergic neurons , 1988, Neuroscience.

[30]  J. L. Vaught.  Substance P antagonists and analgesia: a review of the hypothesis. , 1988, Life sciences.

[31]  K. Jankowski,et al.  Approaches to the Total Synthesis of the Montanine (Amaryllidaceae) Alkaloids. Preparatiion of Isomeric 3-Aryloctahydroindoles , 1985 .

[32]  J. P. Long,et al.  Conformationally restricted congeners of dopamine derived from octahydrobenzo[g]quinoline and octahydrobenzo[f]quinoline. , 1984, Journal of medicinal chemistry.

[33]  S. Chandrasekaran,et al.  Selective Reduction of Nitro Compounds With Titanium(II) Reagents , 1983 .

[34]  R. Madhav.  Synthesis of 1,4-Ethano-3,4-dihydro-2H-1,5-naphthyridines , 1982 .

[35]  F. D. Leeuw,et al.  The relationship between proton-proton NMR coupling constants and substituent electronegativities—I : An empirical generalization of the karplus equation , 1980 .

[36]  C. F. Lane.  SODIUM CYANOBOROHYDRIDE ‐ A HIGHLY SELECTIVE REDUCING AGENT FOR ORGANIC FUNCTIONAL GROUPS , 1975 .

[37]  J. Campbell,et al.  Quinuclidine chemistry. I. Configuration and chemistry of 2-substituted benzylidene-3-quinuclidinones , 1974 .

[38]  Z. Esfandiari,et al.  Model studies of the synthesis of echitamine and related indole alkaloids. , 1972, The Journal of organic chemistry.

[39]  E. Bergmann,et al.  Michael Reactions in the Quinuclidin-3-one Series , 1972 .

[40]  L. Mandell,et al.  A Convenient Synthesis of Tricyclic 2-Quinolizidones1 , 1964 .

[41]  A. Pittman,et al.  The Nitrogen Compounds of Petroleum Distillates. XXVIII. Isolation of 2-Methyl-6,7-dihydro-1,5-pyrindine. Preparation of Some Methyl-dihydro-pyrindines1 , 1960 .

[42]  D. Tivey,et al.  460. Chalcones and related compounds. Part V. Addition of nitro-compounds to chalcones , 1958 .

[43]  A. Müller,et al.  Über Eine Neue Methode zur Darstellung von α‐Pyridonen und Die Synthese des Nicotellins , 1957 .

[44]  T. Haskell,et al.  Catalytic Hydrogenation of Pyridinols, Quinolinols and their Esters , 1944 .